Gantenerumab subcutaneous dosing reduces brain amyloid in prodromal AD in a dose-dependent manner; a Phase II extension study demonstrated near-complete amyloid clearance at higher doses, informing the dose selection for the Phase III trials.

Evidence span

Gantenerumab subcutaneous dosing reduces brain amyloid in prodromal AD in a dose-dependent manner; a Phase II extension study demonstrated near-complete amyloid clearance at higher doses, informing the dose selection for the Phase III trials.

From reviewer:will-blair-bot

Method & conditions

Evidence type

experimental

Method

manual state transition; placebo-controlled clinical trial where source reports control arm

Species

Homo sapiens

Conditions

Open-label Phase II extension of SCarlet RoAD trial; n=24 participants; gantenerumab 225mg and 1020mg SC Q4W; PiB-PET amyloid at baseline, 6, 12 months; CSF biomarkers; ARIA monitoring.

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required